- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-3 Shelf registration
- 1.2 Open Market Sale Agreementsm, Dated June 5, 2020, by and Between AYTU Bioscience, Inc. and Jefferies
- 4.14 Form of Indenture
- 5.1 Opinion of Dorsey & Whitney LLP
- 5.2 Opinion of Dorsey & Whitney LLP
- 23.2 Consent of Plante & Moran, PLLC Relating to Aytu's Financial Statements
- 23.3 Consent of Hall & Company Relating to Innovus' Financial Statements.
- 23.4 Consent of Ernst & Young LLP, Independent Auditors of the Abbreviated Financial Statements of the Pediatrics Product Portfolio of Cerecor Inc.
- 23.5 Consent of Eks&h LLLP, Predecessor Independent Public Accounting Firm, Relating to Aytu's Financial Statements
- 99.1 Unaudited Pro Forma Condensed Combined Statement of Operations for the Year Ended June 30, 2019 and Nine Months Ended March 31, 2020
- 14 Nov 22 424B5 Prospectus supplement for primary offering
- 4 Jun 21 424B3 Prospectus supplement
- 4 Jun 21 424B5 Prospectus supplement for primary offering
- 14 Dec 20 424B5 Prospectus supplement for primary offering
- 11 Dec 20 FWP Free writing prospectus
- 10 Dec 20 FWP Free writing prospectus
- 10 Dec 20 424B5 Prospectus supplement for primary offering
- 18 Jun 20 EFFECT Notice of effectiveness
-
8 Jun 20 S-3 Shelf registration
Exhibit 23.4
Consent of Independent Auditors
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-3) and related Prospectus of Aytu BioScience, Inc. for the registration of $100,000,000 of its common stock, preferred stock, debt securities, warrants, rights, and units and for the registration of $40,000,000 of its common stock and to the incorporation by reference therein of our report dated January 3, 2020, with respect to the abbreviated financial statements of the Pediatrics Product Portfolio of Cerecor Inc. as of September 30, 2019 and December 31, 2018 and for the nine months ended September 30, 2019 and for the year ended December 31, 2018, included in Aytu Bioscience, Inc.’s Current Report on Form 8-K/A dated January 10, 2020, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Baltimore, Maryland
June 5, 2020